Ameriprise’s Acorda Therapeutics ACOR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-439
Closed -$27K 3843
2020
Q3
$27K Buy
+439
New +$33.1K ﹤0.01% 3695
2020
Q2
Sell
-1,924
Closed -$215K 3753
2020
Q1
$215K Sell
1,924
-1,697
-47% -$334K ﹤0.01% 3423
2019
Q4
$886K Buy
3,621
+77
+2% +$19.4K ﹤0.01% 3109
2019
Q3
$1.22M Buy
3,544
+995
+39% +$541K ﹤0.01% 2932
2019
Q2
$2.35M Buy
2,549
+9
+0.4% +$11.1K ﹤0.01% 2650
2019
Q1
$4.05M Buy
2,540
+103
+4% +$186K ﹤0.01% 2357
2018
Q4
$4.56M Buy
2,437
+71
+3% +$155K ﹤0.01% 2175
2018
Q3
$5.58M Sell
2,366
-462
-16% -$1.43M ﹤0.01% 2272
2018
Q2
$9.74M Buy
2,828
+104
+4% +$318K ﹤0.01% 1761
2018
Q1
$7.73M Buy
2,724
+227
+9% +$680K ﹤0.01% 1850
2017
Q4
$6.43M Sell
2,497
-105
-4% -$298K ﹤0.01% 1948
2017
Q3
$7.38M Sell
2,602
-325
-11% -$856K ﹤0.01% 1799
2017
Q2
$6.92M Buy
2,927
+544
+23% +$1.08M ﹤0.01% 1837
2017
Q1
$6.01M Buy
2,383
+84
+4% +$242K ﹤0.01% 1898
2016
Q4
$5.19M Buy
2,299
+22
+1% +$52.3K ﹤0.01% 2022
2016
Q3
$5.7M Sell
2,277
-858
-27% -$2.56M ﹤0.01% 1880
2016
Q2
$9.6M Buy
3,135
+244
+8% +$794K 0.01% 1427
2016
Q1
$9.18M Buy
2,891
+1,132
+64% +$4.7M 0.01% 1486
2015
Q4
$9.03M Sell
1,759
-496
-22% -$2.17M 0.01% 1517
2015
Q3
$7.17M Buy
2,255
+474
+27% +$1.84M ﹤0.01% 1715
2015
Q2
$7.12M Buy
1,781
+54
+3% +$209K ﹤0.01% 1877
2015
Q1
$6.9M Buy
1,727
+94
+6% +$431K ﹤0.01% 1877
2014
Q4
$8.01M Buy
1,633
+1
+0.1% +$4.29K ﹤0.01% 1696
2014
Q3
$6.64M Sell
1,632
-902
-36% -$3.38M ﹤0.01% 1818
2014
Q2
$10.3M Buy
2,534
+1,090
+75% +$4.44M 0.01% 1515
2014
Q1
$6.57M Buy
1,444
+27
+2% +$109K ﹤0.01% 1848
2013
Q4
$4.96M Sell
1,417
-74
-5% -$289K ﹤0.01% 1999
2013
Q3
$6.13M Buy
1,491
+44
+3% +$190K ﹤0.01% 1802
2013
Q2
$5.73M Buy
+1,447
New +$5.96M ﹤0.01% 1806

Other funds holding ACOR

Ameriprise's ACOR Position: Q4 2020 in Review

Ameriprise sold out of Acorda Therapeutics (ACOR) in Q4 2020, closing a stake of 439 shares — an estimated $27K sold.

Ameriprise first reported a position in ACOR in Q2 2013 and held it in 29 quarters. The position peaked at $10.3M in Q2 2014. 47 funds tracked by Wall St. Rank hold ACOR as of Q4 2020.

  • Ameriprise reported no remaining Acorda Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Ameriprise sold 439 Acorda Therapeutics shares in Q4 2020, an estimated $27K.
  • Ameriprise first reported a position in Acorda Therapeutics in Q2 2013 and held it in 29 quarters.
  • Ameriprise's Acorda Therapeutics position peaked at $10.3M in Q2 2014.
  • 47 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2020.

Based on Ameriprise's 13F filing for Q4 2020, filed 12 Feb 2021.